Literature DB >> 25015939

Analysis of outcomes following autologous stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during first complete remission.

Harumi Kato1, Takakazu Kawase2, Shinichi Kako3, Shuichi Mizuta4, Mineo Kurokawa5, Takehiko Mori6, Kazuteru Ohashi7, Koji Iwato8, Koichi Miyamura9, Michihiro Hidaka10, Hisashi Sakamaki7, Ritsuro Suzuki11, Yasuo Morishima12, Junji Tanaka13.   

Abstract

Entities:  

Keywords:  Philadelphia-negative acute lymphoblastic leukemia; autologous stem cell transplantation; first complete remission; outcome

Mesh：

Year:  2014        PMID： 25015939      PMCID： PMC4222457          DOI： 10.3324/haematol.2014.108712

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.

Authors:  S M Davies; N K Ramsay; J P Klein; D J Weisdorf; B Bolwell; J Y Cahn; B M Camitta; R P Gale; S Giralt; C Heilmann; P J Henslee-Downey; R H Herzig; R Hutchinson; A Keating; H M Lazarus; G A Milone; S Neudorf; W S Perez; R L Powles; H G Prentice; G Schiller; G Socié; M Vowels; J Wiley; A Yeager; M M Horowitz
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  O Ringdén; M Labopin; S Tura; W Arcese; A Iriondo; R Zittoun; J Sierra; N C Gorin
Journal:  Br J Haematol       Date:  1996-06       Impact factor: 6.998

3.  Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL.

Authors:  S Giebel; B Stella-Holowiecka; M Krawczyk-Kulis; N Gökbuget; D Hoelzer; M Doubek; J Mayer; B Piatkowska-Jakubas; A B Skotnicki; H Dombret; J M Ribera; P P Piccaluga; T Czerw; S Kyrcz-Krzemien; J Holowiecki
Journal:  Bone Marrow Transplant       Date:  2009-10-26       Impact factor: 5.483

4.  A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Authors:  John E Levine; Richard E Harris; Fausto R Loberiza; James O Armitage; Julie M Vose; Koen Van Besien; Hillard M Lazarus; Mary M Horowitz; Asad Bashey; Brian J Bolwell; Linda J Burns; Mitchell S Cairo; Richard E Champlin; Cesar O Freytes; John Gibson; Steve C Goldstein; Mary J Laughlin; John Lister; David I Marks; Richard T Maziarz; Alan M Miller; Gustavo A Milone; Santiago Pavlovsky; Amdrew L Pecora; J Douglas Rizzo; Gary Schiller; Harry C Schouten; Mei Jie Zhang
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

Review 5.  Novel and emerging drugs for acute lymphoblastic leukemia.

Authors:  E Lech-Maranda; W Mlynarski
Journal:  Curr Cancer Drug Targets       Date:  2012-06       Impact factor: 3.428

6.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.

Authors:  Nicolas Boissel; Marie-Françoise Auclerc; Véronique Lhéritier; Yves Perel; Xavier Thomas; Thierry Leblanc; Philippe Rousselot; Jean-Michel Cayuela; Jean Gabert; Nathalie Fegueux; Christophe Piguet; Françoise Huguet-Rigal; Christian Berthou; Jean-Michel Boiron; Cécile Pautas; Gérard Michel; Denis Fière; Guy Leverger; Hervé Dombret; André Baruchel
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

7.  Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

Authors:  Bella Patel; Lena Rai; Georgina Buck; Sue M Richards; Yeasmin Mortuza; Wayne Mitchell; Gareth Gerrard; Anthony V Moorman; Veronique Duke; A Victor Hoffbrand; Adele K Fielding; Anthony H Goldstone; Letizia Foroni
Journal:  Br J Haematol       Date:  2009-10-26       Impact factor: 6.998

8.  Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Shuichi Mizuta; Keitaro Matsuo; Satoshi Nishiwaki; Kiyotoshi Imai; Heiwa Kanamori; Kazuteru Ohashi; Takahiro Fukuda; Yasushi Onishi; Koichi Miyamura; Satoshi Takahashi; Makoto Onizuka; Yoshiko Atsuta; Ritsuro Suzuki; Yasuo Morishima; Koji Kato; Hisashi Sakamaki; Junji Tanaka
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

9.  Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

Authors:  Jennifer R Brown; Yang Feng; John G Gribben; Donna Neuberg; David C Fisher; Peter Mauch; Lee M Nadler; Arnold S Freedman
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

10.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Authors:  Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.